CD274 and esophageal squamous cell carcinoma: Firstly, to our knowledge, this is the first study using a PSM based on the latest ASTRUM-007 trial to conduct a cost-effectiveness analysis of serplulimab-CF combination therapy in treating PD-L1-positive advanced ESCC.